fbta05
mAbexperimentalMulti-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01138579)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- T cell surface glycoprotein CD3CROSS-LINKING AGENT
T cell surface glycoprotein CD3 cross-linking agent
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
- B-lymphocyte antigen CD20BINDING AGENT
CD20
CD3E
CD3E activator
- B-lymphocyte antigen CD20CROSS-LINKING AGENT
MS4A1 cross-linking agent
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109351 ↗
Also known as
- fbta05
- fbt-a05
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01138579 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2010 | Technical University of Munich |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Technical University of Munich | Academic/Hospital | 1 | 1 | 1 | 2010 |
1 organizations
Page 1 / 1